Anne Li September 16th, 2017 email@example.com
Men with prostate cancer that has spread who are starting long-term hormone therapy may benefit from either of two additional treatments, according to unpublished clinical trial results. The results, based on analysis of data from the Cancer Research UK-funded STAMPEDE trial, show that standard hormone therapy combined with another hormone therapy called abiraterone (Zytiga) or a chemotherapy drug called docetaxel give comparable improvements in survival compared to standard hormone therapy alone.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-09-08-two-treatments-for-advanced-prostate-cancer-bring-equal-benefits
Post a comment